Hemostasis Today

August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Wolfgang Miesbach: Haemophilia and Ageing – A Joint ISTH/EAHAD Session at ISTH 2026
Aug 25, 2026, 11:25

Wolfgang Miesbach: Haemophilia and Ageing – A Joint ISTH/EAHAD Session at ISTH 2026

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared post on LinkedIn:

“Haemophilia and ageing – a joint ISTH/EAHAD session at ISTH 2026.

As our patients grow older, the questions we face are no longer only about bleeding.

Three complementary perspectives – Thomas Caprio, Robert Klamroth and Andreas Strauss – mapped how ageing is reshaping haemophilia care.

Robert Klamroth’s talk on balancing the risks between thrombosis and bleeding captured the shift particularly well:

  • The population has aged

In US registries, the more than 65 group has grown from nearly 2% (2011) to 5% (2023), while the less than 45s have fallen from 86% to 76%.

Cardiovascular disease is now a routine comorbidity, not an exception.

  • Causes of death are changing

EUHASS 2024 data show cardiac events and intracranial haemorrhage alongside bleeding as leading causes – raising the key question: can we reduce these?

  • Hypertension is more prevalent

Higher in PWH aged 50–59 vs the general population (H3 vs DEGS1), yet management is no different – and measurement is simple.

  • ‘Naturally anticoagulated’ needs revisiting

In the prophylaxis and non-factor era, this assumption no longer holds.

Data (van der Valk, Blood Adv 2022; COCHE) suggest antithrombotic treatment can be delivered safely – with appropriate factor cover.

The open questions that will define the coming years:

  • Are PWH still ‘naturally anticoagulated’ in the modern era?
  • Do non-factor therapies alter thrombotic risk?
  • Are rebalancing agents changing risk stratification altogether?”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.